Drugs / H3N2 M2SR monovalent influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02822105 | Jun 2016 → Apr 2017 | influenza | FluGen Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3N2 M2SR monovalent influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02822105 ↗ |
| Known as | Bris10 M2SR | “The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and...” NCT02822105 ↗ |
| Modality | Vaccine | “H3N2 M2SR influenza vaccine” NCT02822105 ↗ |
| Route | Intranasal | “administered intranasally” NCT02822105 ↗ |